Intra-Cellular Therapies (ITCI) Sinks 69% as Trading Resumes
Article Related Press Releases (1) Related Articles (4) Related SEC Filings (1) Stock Quotes (1) Comments (0)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Intra-Cellular Therapies (NASDAQ: ITCI) sinks 68.7% as trading resumes following trial failure.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Acacia Communications (ACIA) Mentioned as Short in Lakewood Capital's Q3 Letter - Bloomberg
- Intel (INTC) February 37.5, 38 and 39 calls active into Q4
- Southwest Airlines (LUV) call put ratio 1 call to 6.7 puts into Q4 and outlook
Create E-mail Alert Related CategoriesFDA, Hot FDA News, Trader Talk, Trading Halts
Related EntitiesThe Children's Investment Fund (TCI)
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!